Epoetin Beta and C‐Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease

BACKGROUND: In patients with chronic heart failure and chronic kidney disease, correction of anemia with erythropoietin‐stimulating agents targeting normal hemoglobin levels is associated with an increased risk of cardiovascular morbidity and mortality. Emerging data suggest a direct effect of eryth...

Descripción completa

Detalles Bibliográficos
Autores principales: Eisenga, Michele F., Emans, Mireille E., van der Putten, Karien, Cramer, Maarten J., Diepenbroek, Adry, Velthuis, Birgitta K., Doevendans, Pieter A., Verhaar, Marianne C., Joles, Jaap A., Bakker, Stephan J. L., Nolte, Ilja M., Braam, Branko, Gaillard, Carlo A. J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759901/
https://www.ncbi.nlm.nih.gov/pubmed/31423921
http://dx.doi.org/10.1161/JAHA.118.011130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759901/
https://www.ncbi.nlm.nih.gov/pubmed/31423921
http://dx.doi.org/10.1161/JAHA.118.011130

Ejemplares similares